Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection
Annovis Bio (NYSE: ANVS) has been granted a U.S. patent for using buntanetap in the treatment and prevention of acute brain or nerve injuries. The patent, issued on January 2, 2025, extends the company's global protection, as similar patents have already been granted in the EU, Japan, and other regions worldwide.
The patent is based on buntanetap's capability to reduce neurotoxicity and mitigate neurodegenerative processes, making it potentially applicable to conditions such as stroke, ischemia, traumatic brain injury, micro infarcts, and other acute injuries. This expands the potential applications of buntanetap beyond its primary indications of Alzheimer's and Parkinson's diseases.
Annovis Bio (NYSE: ANVS) ha ottenuto un brevetto statunitense per l'uso di buntanetap nel trattamento e nella prevenzione di lesioni acute al cervello o ai nervi. Il brevetto, rilasciato il 2 gennaio 2025, amplia la protezione globale dell'azienda, poiché brevetti simili sono già stati concessi nell'UE, in Giappone e in altre regioni del mondo.
Il brevetto si basa sulla capacità di buntanetap di ridurre la neurotossicità e mitigare i processi neurodegenerativi, rendendolo potenzialmente applicabile a condizioni come ictus, ischemia, trauma cranico, microinfarti e altre lesioni acute. Questo espande le potenziali applicazioni di buntanetap oltre le sue indicazioni principali di morbo di Alzheimer e morbo di Parkinson.
Annovis Bio (NYSE: ANVS) ha recibido una patente estadounidense para el uso de buntanetap en el tratamiento y la prevención de lesiones agudas en el cerebro o los nervios. La patente, emitida el 2 de enero de 2025, amplía la protección global de la empresa, ya que patentes similares ya han sido otorgadas en la UE, Japón y otras regiones del mundo.
La patente se basa en la capacidad de buntanetap para reducir la neurotoxicidad y mitigar los procesos neurodegenerativos, lo que lo hace potencialmente aplicable a condiciones como accidente cerebrovascular, isquemia, traumatismo craneoencefálico, microinfartos y otras lesiones agudas. Esto amplía las posibles aplicaciones de buntanetap más allá de sus indicaciones primarias de las enfermedades de Alzheimer y Parkinson.
Annovis Bio (NYSE: ANVS)는 buntanetap을 급성 뇌 또는 신경 손상의 치료 및 예방에 사용하는 미국 특허를 부여받았습니다. 2025년 1월 2일에 발급된 이 특허는 회사의 전 세계 보호를 확장하며, 유럽연합, 일본 및 기타 지역에서도 유사한 특허가 이미 부여되었습니다.
이 특허는 buntanetap의 신경독성 감소 및 신경퇴행성 과정 완화 능력을 기반으로 하여, 뇌졸중, 허혈, 외상성 뇌손상, 미세경색 및 기타 급성 손상과 같은 상태에 적용 가능성을 시사합니다. 이는 buntanetap의 주요 적응증인 알츠하이머병 및 파킨슨병을 넘어서는 잠재적 적용 범위를 확장합니다.
Annovis Bio (NYSE: ANVS) a obtenu un brevet américain pour l'utilisation de buntanetap dans le traitement et la prévention des blessures aiguës au cerveau ou aux nerfs. Le brevet, délivré le 2 janvier 2025, étend la protection mondiale de l'entreprise, car des brevets similaires ont déjà été accordés dans l'UE, au Japon et dans d'autres régions du monde.
Le brevet repose sur la capacité de buntanetap à réduire la neurotoxicité et à atténuer les processus neurodégénératifs, ce qui le rend potentiellement applicable à des conditions telles que AVC, ischémie, traumatisme crânien, micro-infarctus et autres blessures aiguës. Cela élargit les applications potentielles de buntanetap au-delà de ses indications principales de la maladie d'Alzheimer et de la maladie de Parkinson.
Annovis Bio (NYSE: ANVS) hat ein US-Patent für die Verwendung von buntanetap zur Behandlung und Prävention akuter Gehirn- oder Nervenverletzungen erhalten. Das Patent, das am 2. Januar 2025 erteilt wurde, erweitert den globalen Schutz des Unternehmens, da ähnliche Patente bereits in der EU, Japan und anderen Regionen der Welt erteilt wurden.
Das Patent basiert auf der Fähigkeit von buntanetap, Neurotoxizität zu reduzieren und neurodegenerative Prozesse zu mildern, was es potenziell anwendbar auf Zustände wie Schlaganfall, Ischämie, traumatische Hirnverletzung, Mikroinfarkte und andere akute Verletzungen macht. Dies erweitert die potenziellen Anwendungen von buntanetap über seine Hauptindikationen für Alzheimer- und Parkinson-Krankheit hinaus.
- Secured U.S. patent protection for buntanetap in acute brain/nerve injuries
- Achieved complete global patent protection including EU, Japan, and other regions
- Expanded potential market applications beyond primary indications (Alzheimer's and Parkinson's)
- None.
Insights
The newly granted U.S. patent significantly strengthens Annovis Bio's IP portfolio by providing comprehensive global protection for buntanetap in acute brain injuries. The patent's scope covers multiple high-value indications including stroke, traumatic brain injury and ischemia, expanding beyond their core focus on chronic neurodegenerative diseases. This strategic IP expansion creates multiple commercialization pathways and potential licensing opportunities.
The patent's timing aligns with the increasing market demand for acute brain injury treatments, particularly as stroke remains a leading cause of disability. Having secured protection in major markets (U.S., EU, Japan), Annovis now has exclusive rights until at least 2040, creating significant barriers to entry for competitors. This comprehensive IP shield enhances the company's negotiating position for potential partnerships or acquisitions.
Buntanetap's mechanism targeting neurotoxic pathways represents a novel approach in acute brain injury treatment. Current treatments primarily focus on symptom management rather than addressing underlying neurotoxicity. The drug's potential to both prevent and treat acute injuries suggests versatile clinical applications - from emergency medicine to preventive care in high-risk patients.
In simple terms, imagine buntanetap as a shield that protects brain cells during moments of crisis (like stroke or injury) while also helping repair already damaged cells. This dual action differentiates it from existing treatments. The global protection now secured means this innovative approach could become available worldwide, potentially transforming acute brain injury care.
This patent significantly enhances Annovis's market positioning in the $50+ billion global neurology market. While the company's primary focus remains on chronic conditions like Alzheimer's and Parkinson's, this expansion into acute injuries opens substantial new market opportunities. The acute brain injury treatment market alone is projected to reach $12.6 billion by 2028, with stroke care representing the largest segment.
For a company with a market cap of just
MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced it was granted the U.S. patent covering methods for the treatment and prevention of acute brain or nerve injuries using buntanetap.
This newly issued patent is based on buntanetap’s ability to reduce neurotoxicity and mitigate neurodegenerative processes, which can be applicable to such conditions as stroke, ischemia, traumatic brain injury, micro infarcts, and other forms of acute injuries. The patent has already been granted in the EU, Japan, and worldwide. With this latest approval in the U.S., the company now holds global protection for the use of buntanetap in treating acute neurodegenerative disorders.
“Nerve cells are inherently delicate and susceptible to structural damage upon physical impact. Buntanetap works by targeting the neurotoxic pathways that contribute to this damage, providing a potential path to protect and restore neuronal health,” commented Maria Maccecchini, Ph.D., Founder, President and CEO of Annovis. “We are proud to add this patent to our growing intellectual property portfolio, further expanding the possible applications of buntanetap beyond its primary indications such as Alzheimer’s and Parkinson’s diseases.”
The U.S. Patent and Trademark Office (USPTO) issued the patent on January 2, 2025, under the publication number US-2025-0000846-A1.
About Annovis Bio
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com
FAQ
What is the new U.S. patent granted to Annovis Bio (ANVS) for buntanetap?
What medical conditions could buntanetap potentially treat according to ANVS's new patent?
Where does Annovis Bio (ANVS) now hold patent protection for buntanetap?
How does buntanetap work in treating brain injuries according to ANVS?
